Drug Profile
Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics
Alternative Names: AMRS-001; CDNF - MANF Therapeutics; Cerebral dopamine neurotrophic factor - MANF Therapeutics; Conserved dopaminergic neurotrophic factor; MANF-based therapeutics - MANF Therapeutics; Mesencephalic astrocyte-derived neurotrophic factor; Recombinant MANF - MANF Therapeutics; rhMANF - MANF TherapeuticsLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Amarantus Therapeutics; University of Miami
- Developer Amarantus Bioscience Holdings; Generex Biotechnology Corporation; MANF Therapeutics
- Class Antidementias; Antihyperglycaemics; Antiparkinsonians; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Recombinant proteins; Vascular disorder therapies
- Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Diabetes mellitus; Glaucoma; Ischaemic heart disorders; Macular degeneration; Parkinson's disease; Retinal artery occlusion; Retinal vein occlusion; Retinitis pigmentosa; Spinocerebellar degeneration; Stroke
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Glaucoma in USA (Intravitreous, Injection)